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The Specific Vulnerabilities 
of Cancer Cells to the Cold 
Atmospheric Plasma-Stimulated 
Solutions
Dayun Yan1, Haitao Cui1, Wei Zhu1, Niki Nourmohammadi2, Julian Milberg3, Lijie G. Zhang1, 
Jonathan H. Sherman4 & Michael Keidar1
Cold atmospheric plasma (CAP), a novel promising anti-cancer modality, has shown its selective anti-
cancer capacity on dozens of cancer cell lines in vitro and on subcutaneous xenograft tumors in mice. 
Over the past five years, the CAP-stimulated solutions (PSS) have also shown their selective anti-
cancer effect over different cancers in vitro and in vivo. The solutions used to make PSS include several 
bio-adaptable solutions, mainly cell culture medium and simple buffered solutions. Both the CAP-
stimulated medium (PSM) and the CAP-stimulated buffered solution (PSB) are able to significantly kill 
cancer cells in vitro. In this study, we systematically compared the anti-cancer effect of PSM and PSB 
over pancreatic adenocarcinoma cells and glioblastoma cells. We demonstrated that pancreatic cancer 
cells and glioblastoma cells were specifically vulnerable to PSM and PSB, respectively. The specific 
response such as the rise of intracellular reactive oxygen species of two cancer cell lines to the H2O2-
containing environments might result in the specific vulnerabilities to PSM and PSB. In addition, we 
demonstrated a basic guideline that the toxicity of PSS on cancer cells could be significantly modulated 
through controlling the dilutability of solution.
Cold atmospheric plasma (CAP) is a near room temperature ionized gas composed of charged particles, neutral 
particles, and electrons1. Among these particles, the oxygen-based reactive species and the nitrogen-based reac-
tive species may mainly contribute to the interaction between CAP and cells2–6. Over the past decade, CAP has 
shown its remarkably selective anti-cancer capacity in vitro5–9. Moreover, CAP is able to significantly reduce the 
size of subcutaneous xenograft tumors in mice models by a direct treatment just above the skin10–15. The direct 
CAP treatments rely upon a CAP generating device during the treatment. Over the past five years, the indirect 
CAP treatment became a new topic in plasma medicine. The indirect CAP treatment uses the CAP-treated bio-
logically adaptable solutions (PSS) to affect the growth of cancer cells in vitro13, 16–30 or in vivo by injecting PSS into 
the tumor tissues17, 30. PSS can be stored over a long time length at −80 °C20, 26 by optimizing the composition of 
the solution24. Thus, PSS can be used without the dependence on the CAP generating device. In addition, cancer 
cells were actually covered by a thin layer of medium or other simple buffered solutions during the direct CAP 
treatment15, 31, 32. This thin layer of solution facilitates the transition of the CAP-originated reactive species in the 
gas phase to be the dissolved species in the aqueous solutions5, 33. Thus, the study of PSS will also facilitate the 
understanding on the direct CAP treatment.
Compared with the abundant studies on the direct CAP treatment, the understanding of the anti-cancer effect 
of PSS is lacking. To date, only four biologically adaptable solutions have been used as PSS. Most studies used cell 
culture medium to make PSS13, 16–30, 34–36. Few studies used simple buffered solutions such as phosphate buffered 
solution (PBS)24, 36, 37 and Lactated Ringer’s solution30 to make PSS. To investigate the anti-cancer capacity of PSS 
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in vitro, at least three research strategies have been proposed (Fig. 1). In this study, the CAP-stimulated medium 
and the CAP-stimulated simple buffered solution is designated as PSM and PSB, respectively. Considering the 
fact that medium as the control is suitable for cell culture over a long time, PSM can be used to culture cancer cells 
overnight13, 16–30, 34–36. Whereas, the simple buffered solutions without the necessary nutrients can be just used 
to affect the cancer cells for a relative short time such as several hours. At least two research strategies have been 
developed for PSB. One is directly using PSB to affect cancer cells for a short time length such as several hours30. 
After that, PSB is replaced by the untreated medium. The cancer cells will be cultured in the new medium over-
night until the final cell viability assay or other analysis is performed. Another strategy is using the mixture of PSB 
and the untreated medium to culture cells overnight. In this case, despite the medium will be diluted by PSB, its 
nutrient will still sustain the growth of cancer cells overnight24.
The understanding of the anti-cancer mechanism of PSM has been extensively investigated. The CAP-original 
reactive species such as H2O218, 20–22, 24, 26, 34, NO2− 27, 37, as well as NO3− 27, 37 have been regarded as the key 
anti-cancer species in PSM. Catalase or other simple chemicals such as cysteine and methionine can effectively 
eliminate the anti-cancer capacity of PSM through consuming H2O220, 21, 38. Thus, H2O2 may be a key anti-cancer 
species formed in PSM. H2O2 can cause DNA damage on cancer cells, which is mediated by hydroxyl radicals gen-
erated from H2O2 by the Fenton reaction39. H2O2 is also an efficient inductor for the apoptosis in cancer cells39, 40. 
H2O2-generating drugs can effectively kill cancer cells by the increase of cellular levels of H2O239. Experimental 
evidences demonstrate that cancer cells are more susceptible to H2O2 with specific concentration than normal 
cells39, 41, 42. Moreover, increasing the concentration of reactive species in PSM by chemical methods20, 24 or phys-
ical methods21 is an effective strategy to optimize the anti-cancer capacity of PSM.
Whereas, the understanding on the anti-cancer mechanism of PSB is just limited to few refs 24, 30, 36 and 37. 
The anti-cancer capacity of PSB is highly affected by the research strategies chosen by authors. Compared with 
PSM, the killing effect of PSB is always weaker. As early as in 2011, Sameer Kalghatgi, et al. first found that 
noticeable double strand DNA breaks just occurred in the CAP treatment on medium rather than on PBS43. Very 
recently, Hiromasa Tanaka, et al. found that the CAP-treated water could not cause the noticeable killing effect 
on glioblastoma cells (U251SP)30. Corresponding noticeable rise of intracellular reactive oxygen species (ROS) 
just occurred in the cells cultured in PSM rather than in PSB30. In fact, the H2O2 generation in PSM and PSB are 
similar in these cases30. These contradictions indicate that just the reactive species in PSB may not necessarily 
result in a noticeable damage on cancer cells. However, it is widely observed that the reactive species in PSM 
would definitely cause noticeable cancer cells death13, 16–30, 34–36. In addition, we have found that using the PSB/
untreated DMEM mixture could also achieve a significant anti-cancer effect over glioblastoma cells (U87MG), 
pancreatic adenocarcinoma cells (PA-TU-8988T), as well as breast adenocarcinoma cells (MDA-MB-231). In 
short, the anti-cancer species may be toxic to cancer cells just in PSM or PSB/medium mixture rather than in PSB. 
The unique characteristics differentiating PSM and PSB, and their subsequent interaction on cancer cells have yet 
to be elucidated.
In this study, we systematically compared the anti-cancer effect of PSM and PSB on two cancer cell lines, 
U87MG and PA-TU-8988T. We identified that the effect on cancer cells is cell-dependent and dose-dependent. 
Both PSM and PSB could inhibit the growth of cancer cell lines when the right experimental conditions were set. 
Figure 1. Typical strategies of using PSS to affect the growth of cancer cells in vitro. The differences between 
these strategies are just due to one fact that a simple buffered solution such as PBS and Lactated Ringer’s 
solution cannot be used to culture cells over a relative long time length. Step ①: Making PSM/PSB by treating 
the solutions with CAP. Step ②: Using PSM/PSB to affect the growth of cancer cells. Step ③: Culturing the cancer 
cells in PSM or medium overnights until the final cell viability assay. PSM: CAP-stimulated medium. PSB: CAP-
stimulated simple buffered solution.
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U87MG cells and PA-TU-8998T cells were highly vulnerable to PSB and PSM, respectively. The measurement of 
intracellular ROS of two cell lines in PSM and PSB first revealed that the different cellular responses in medium 
and in PBS might cause the different vulnerabilities of cells to PSM and PSB.
Methods
CAP device. The CAP jet device was designed and assembled in our lab and has been used in a series of 
studies about the anti-cancer capacity of the CAP treatment in vitro19, 21, 25, 44, 45 and in vivo10. It used helium as 
the carrying gas. The CAP jet was formed by the discharge between a ring grounded cathode and a central anode 
and was flowed out (4.7 L/min) the quartz tube with a diameter of 4.5 mm. The input voltage of DC power was 
11.5 V. The output voltage was 3.16 kV. The plasma discharge was driven by an AC high voltage with a frequency 
of 30 kHz.
Cells culture. Human glioblastoma (U87MG) cells and human pancreas adenocarcinoma (PA-TU-8988T) 
cells were provided by Dr. Murad’s lab at the George Washington University. Human breast adenocarcinoma cells 
(MDA-MB-231) were provided by Dr. Zhang’s lab at the George Washington University, and were cultured in 
the same protocol as previous studies46, 47. The Dulbecco’s modified Eagle’s medium (DMEM, with L-glutamine, 
11965–118) was purchased from Life Technologies. DMEM was mixed with 1% (v/v) antibiotic (penicillin and 
streptomycin) solution (Life Technologies). The media used in cell culture were composed of DMEM supple-
mented with 10% (v/v) fetal bovine serum (ThermoFisher Scientific). All wells on the margins of a 96-wells plate 
(61406–081, Corning) were not used in this study. Only 6 wells in a single column on a 96-wells plate were used 
to seed cells. 100 μL of the cells-harvesting solution (6 × 104 cells/mL) were seeded in each well. Cancer cells were 
grown for 1 day under the standard culture condition (a humidified, 37 °C, 5% CO2 environment). The media that 
have been used to culture cells overnight were removed before using PSM or PSB to treat cancer cells.
Extracellular H2O2 assay. The H2O2 concentration in sample solutions was measured by using Fluorimetric 
Hydrogen Peroxide Assay Kit (Sigma-Aldrich) following the protocols provided by manufacturer. Finally, 50 μL 
of H2O2 probe solution was mixed with 50 μL of sample in the black 96-wells plate. After 30 min of storage at the 
room temperature without the ambient light, the fluorescence was measured by a H1 microplate reader (Hybrid 
Technology) at 540/590 nm. The final fluorescent strength of the experimental group was obtained by deducting 
the fluorescence of the control group from the fluorescence of the experimental group. The H2O2 concentration 
in the samples were calculated based on the standard curve. In each experiment, the sample number was 3. The 
average of 3 samples was set as one result.
Making (N-acetyl-L-cysteine) NAC containing DMEM (NAC-DMEM) and pre-treating can-
cer cells. 6 mM and 10 mM NAC-DMEM were made by dissolving NAC powder (A7250, Sigma-Aldrich) 
in DMEM. As an intracellular ROS scavenger, NAC will penetrate the cytoplasmic membrane and resist the 
redox balance change due to the rise of intracellular ROS13, 17, 48. To pre-treat cancer cells with NAC-DMEM, the 
medium which has been used to culture cancer cells overnight were removed first. Then, 100 μL of NAC-DMEM 
were used to culture the cancer cells in each well of a 96-wells plate. After 3 hr, the NAC-DMEM were removed. 
These cancer cells were ready for the further treatment.
Making PSM/PSB, H2O2-containing DMEM/PBS (H2O2-DMEM/PBS), NO2−-containing DMEM 
(NO2−-DMEM) and treating cancer cells. In this study, Lonza BioWhittaker Dulbecco’s PBS did not 
contain calcium and magnesium (BW17512F12, Fisher Scientific). To make PSM/PSB, 1 mL of DMEM in a well 
of a 12-wells plate (61406–165, Corning) was treated by CAP. The gap between the bottom of 12-wells plate and 
the CAP source was 3 cm. To make H2O2-DMEM/PBS, 9.8 M H2O2 standard solution (216763, Sigma-Aldrich) 
were added in DMEM or PBS with a designed concentration. Similarly, to make NO2−-DMEM, 0.1 M nitrite ion 
standard solution (72586, Sigma-Aldrich) was added in DMEM with a designed concentration. To affect the 
growth of cancer cells, 100 μL of the prepared solutions including PSM/PSB, H2O2-DMEM/PBS, NO2−-DMEM 
was transferred to affect cancer cells grown on a 96-wells plate immediately after the preparation. For the control 
group, cancer cells were just cultured in the untreated DMEM or in the untreated PBS. In each experiment, the 
sample number was 6. For the experiment using the PBS-based solutions, cancer cells were just cultured in the 
CAP-stimulated PBS for 3 hr. The new DMEM replaced the CAP-stimulated PBS after that and further sustained 
the culture for 1 day. For the experiment using DMEM, cancer cells were cultured for 1 day after the treatment. 
These sextuplicate experiments were independently repeated for at least twice.
Measuring the H2O2 consumption speed by cancer cells. The protocols for different cancer cell lines 
were identical. Here, we used U87MG cells as an example. First, 100 μL of cells harvesting solution with a conflu-
ence of 6 × 104 cells/mL were seeded in a well on a 96-wells plate. In each experiment, 3 wells on 96-wells plate 
were seeded with cells as 3 samples. Cells were cultured in the incubator for 7 hr under the standard conditions. 
Then, 1 mL of DMEM or PBS in a well on a 12-wells plate was treated by CAP for 1 min. After that, 100 μL of PSM 
or PSB was transferred to culture cells grown on a 96-wells plate. The medium which has been used to culture cells 
was removed before this step. Since then, 50 μL of medium which has been used to culture cells was transferred 
to a well on a black clear bottom 96-wells plate (29444–008, Corning) in triplicate every hour until the third hour. 
Ultimately, the residual H2O2 concentration in PSM or PSB was measured using fluorimetric assay illustrated 
above.
Making the diluted PSM and affecting cancer cells. We prepared a series of diluted DMEM by grad-
ually increasing the dilution fraction of PBS in DMEM from 0% to be 90%. The corresponding dilutability of 
DMEM gradually decreased from 0% to be 90%. Because cancer cells needed to be cultured overnight, we have 
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not performed the experiment with a 100% of dilutability. Then, 1 mL of DMEM with different dilutabilities in 
a well of 12-wells plate (61406–165, Corning) was treated by CAP. The gap between the bottom of 12-wells plate 
and the CAP source was 3 cm. To affect the growth of cancer cells, 150 μL of PSM with different dilutabilities was 
transferred to affect cancer cells grown on a 96-wells plate immediately. In control groups, cancer cells were just 
cultured in the untreated DMEM with different dilutabilities. In each experiment, the sample number was 6. 
Cancer cells were cultured for 1 day before the cell viability assay. All experiments were independently repeated 
for at least 3 times in sextuplicate.
Cell viability assay. The cell viability was measured by using MTT (3-(4,5-Dimethyl-2-thiazol)-
2,5-Diphenyl-2H-tetrazolium Bromide) assay following the standard protocols provided by manufacturer 
(M2128, Sigma-Aldrich). The 96-wells plate was read by a H1 microplate reader (Hybrid Technology) at an 
absorbance of 570 nm. To facilitate the formation of final violet solution, the 96-wells plates were shook for 30 s 
before reading. To facilitate the data analysis, the measured absorbance at 570 nm was processed to be a relative 
cell viability by the division of absorbance between the experimental group and the control group. In each exper-
iment, the cell viability was equal to the mean of 6 samples from 6 wells.
Measuring intracellular ROS. The cell permeant 2,7-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA), a general oxidative stress indicator (ThermoFisher Scientific) has been widely used as the 
intracellular ROS probes in plasma medicine, though the determination of intracellular ROS by these probes may 
be influenced by the level of free cytochrome c in cells49. 500 mL of 1× buffer (113851, Abcam) were added into 
the tube containing 50 μg of molecular probes CM-H2DCFD to prepare the 1× stock solution. 1× stock solution 
was further diluted to be 0.03125× stock solution. Prior to the measurement, 100 μL of 25 × 104 cells/mL cells 
were seeded in the well on a black clear bottom 96-wells plate (29444–008, Corning) and were cultured for 1 
day. For each case, the samples in experimental group and control group were all 3. The controls groups and the 
experimental groups were the measurements performed on cancer cells just cultured in the untreated DMEM/
PBS and in the H2O2-DMEM/PBS, respectively. The 10 min- and 20 min-equivalent H2O2-DMEM/PBS were pre-
pared by adding 30 wt % (9.8 M) H2O2 solution (216763, Sigma-Aldrich) in DMEM/PBS. The concentration of 
10 min- and 20 min-equivalent H2O2-DMEM/PBS were 367.5 μM and 735 μM, respectively. The intracellular ROS 
measurement of PA-TU-8988T cells and U87MG cells began 3 hr and 50 min after the H2O2 treatment on cells, 
respectively. Cells were washed by 100 μL of 1× buffer. Then, cells were cultured in 100 μL of 0.03125× stock 
solution for 50 min. Subsequently, 100 μL of PBS was used to replace the stock solution in each well. Finally, the 
fluorescence was measured by a H1 microplate reader (Hybrid Technology) at 485/535 nm. For the data process-
ing, the measured fluorescence of the control groups and the experimental groups were first subtracted by the 
fluorescence of background (just PBS). The fluorescence of the experimental group was modified by subtract-
ing the fluorescence of the control group. Ultimately, the modified fluorescence of the experimental groups was 
modified to be a relative intracellular ROS based on the following formula. Relative intracellular ROS = Modified 
experimental groups/Modified control group.
Data availability statement. All data generated or analysed during this study are included in this pub-
lished article (and its Supplementary Information files).
Experiments and results. PBS cannot be used to culture cancer cells for a relative long time. In the first 
study about the toxicity of PSB on mammalian breast epithelial cells (MCF10A), the cells were just immerged 
in PBS for a short time length43. In this study, PSB was only used to affect the growth of cancer cells for several 
hours before we used the untreated DMEM to replace PSB and further sustain the culture overnight. Finding 
a proper culture time for the cancer cells in PSB is necessary for an effective comparison with PSM. In plasma, 
the common way to use PSM is just culturing cells in PSM overnight or for several days (Fig. 1). Thus, we first 
investigated whether the initial several hours of culture were important for the toxicity of PSM on PA-TU-8988T 
cells. Specifically, PA-TU-8988T cells grown on a 96-wells plate were cultured for 24 hours. Following the proto-
cols in methods about making PSM, 1 mL of PSM were made by a 3 min of CAP treatment on DMEM. 100 μL of 
PSM was transferred to affect the growth of PA-TU-8988T cells immediately. Afterward, 100 μL of new DMEM 
replaced PSM to culture cancer cells and changed every hour after the treatment until the fourth hour (Fig. 2a). 
Finally, PA-TU-8988T cells were cultured for 24 hours followed by the cell viability assay according the protocols 
in Methods. For MDA-MB-231 cells, the protocols were similar except the CAP treatment was performed on 
6-wells plate for 1 min with the same changing of media as above.
It is found that removing the PSM which has been cultured with the cancer cells for 2 to 4 hr could not change 
the toxicity of PSM on MDA-MB-231 cells and PA-TU-8988T cell viability (Fig. 2a and b). The noticeably weak-
ened anti-cancer capacity only occurred when PSM was removed prior to 1 hr after the initiation of treatment 
(Fig. 2a and b). To further confirm this trend, we investigated the anti-cancer capacity of PSM on PA-TU-8988T 
cells by replacing PSM with new DMEM 3 hr after using PSM to affect cells. PSM was made by treating 1 mL of 
DMEM in a 12-wells plate with CAP. Compared with the case that just culturing PA-TU-8988T cells in PSM for 
1 day, removing PSM from the culturing environment of PA-TU-8988T cells just 3 hr after the treatment, did not 
produce noticeable difference in terms of anti-cancer capacity (Fig. 2c).
These observations indicate that the anti-cancer reactive species in PSM has been significantly consumed in 
the initial several hours after the CAP treatment. Thus, we further investigated the residual H2O2 concentration 
in PSM and PSB which was used to culture cancer cells for several hours. The protocols are illustrated in Methods. 
We identified a significant consumption of H2O2 in PSM by the two cancer cell lines in the initial 3 hr (Fig. 2d). 
U87MG cells consumed H2O2 faster than PA-TU-8988T cells did. In addition, the two cancer cell lines consumed 
H2O2 at slightly faster rate in DMEM than that in PBS (Fig. 2d). The H2O2 in PSM has been completely consumed 
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by U87MG cells just 2 hr after the treatment. The residual H2O2 in PSM and PSB have nearly been completely 
consumed by two cell lines just in the initial 3 hr after the treatment. This result is consistent with the observation 
that replacing PSM by new DMEM 3 hr after the treatment will not affect the anti-cancer capacity of PSM.
To compare the anti-cancer capacity of PSM and PSB, DMEM and PBS were treated by the CAP jet under the 
same experimental conditions. The killing effect of PSM and PSB on cancer cells will be noticeable as long as the 
treatment time was longer than 2 min. PSM was much more toxic to PA-TU-8988T cells than PSB when the CAP 
treatment time was longer than 3 min (Fig. 3a). In contrast, PSB was much more toxic to U87MG cells than PSM 
when the CAP treatment time was longer than 2 min (Fig. 3b). Pre-treating cancer cells with the intracellular 
ROS scavengers such as D-mannitol48, rotenone50, apocynin50, as well as NAC13, 48, 51 can drastically counteract 
the anti-cancer effect of CAP treatment. We further investigated the effect of NAC on the anti-cancer effect of 
PSM and PSB. As shown in Fig. 3c and d, both 6 mM and 10 mM NAC could completely inhibit the killing effect 
of PSM in the two cell lines. Particularly, for U87MG cells, 10 mM NAC resulted in a noticeably higher cell via-
bility than 6 mM NAC does (Fig. 3d). On the contrary, the pre-treatment of NAC showed remarkably different 
effects on the toxicity of PSB between two cell lines. For the PSB-treated U87MG cells, 6 mM NAC did not cause 
a noticeable increase on the cell viability (Fig. 3d). However, 10 mM NAC significantly increased the cell viability 
about 100% compared the cells treated by the PSB made by 5 min of CAP treatment. (Fig. 3d). For PA-TU-8988T 
cells, both 6 mM and 10 mM NAC could not noticeably increase the viability of the PSB-treated cancer cells 
(Fig. 3c). Based on these results, it appears that the two cell lines experience different cellular responses in PSM 
and in PSB that lead to the decrease of tumor cell viability with different levels.
The CAP-originated reactive species including ROS and RNS have been regarded as the main anti-cancer 
factors during the CAP treatment in vitro5. Despite many researchers regard H2O2 as the main anti-cancer species 
generated by the CAP treatment18, 20–22, 24, 26, 34, 52–54, it is still disputable that RNS might be a key anti-cancer spe-
cies55. We analyzed the role of NO2−, a widely confirmed CAP-originated RNS product53, 56, 57 in the anti-cancer 
capacity of PSM. The NO2−concentration in PSM made by 1 min of CAP treatment was approximately 10 μM. 
The toxicity on cancer cells of concentrations ranging from 100 μM to 900 μM NO2−-DMEM on PA-TU-8988T 
cells, U87MG cells, as well as MDA-MB-231 cells were studied. Clearly, even 900 μM NO2−-DMEM which was 
equivalent to a PSM experienced about 90 min of CAP treatment would not noticeably inhibit the growth of all 
Figure 2. The initial several hours after the treatment are key for the anti-cancer effect of PSS. After the 
treatment for 2 to 4 hr, removing the PSM from cancer cells’ environment would not affect the anti-cancer effect 
on PA-TU-8988T cells (a) and MDA-MB-231 cells (b). No change means that PSM were used to culture cancer 
cells for 1 day without renewing the medium. (c) After the treatment for 3 hr, replacing the CAP-stimulated 
(CAP’s) DMEM by the untreated DMEM just caused a similar anti-cancer effect on PA-TU-8988T cells as using 
the CAP’s DMEM to affect cells did. (d) The extracellular H2O2 were completely consumed by cancer cells in 
just 3 hr after the treatment. Results in (a), (b) and (c) are presented as the mean ± s.d. of two independently 
repeated experiments performed in sextuplicate. Results in (d) are presented as the mean ± s.d. of two 
independently repeated experiments performed in triplicate.
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three cell lines at all (Figs 4 and S1). Thus, NO2− at least does not independently contribute to the toxicity of PSM 
to cancer cells.
The toxicity of H2O2-DMEM and H2O2-PBS on PA-TU-8988T cells and U87MG cells were also investigated. 
We identified that 1 min of CAP treatment in DMEM or PBS would generate 36.3 μM H2O2. Thus, 36.3 μM 
H2O2-DMEM/PBS was the 1 min- equivalent CAP-stimulated DMEM/PBS. As shown in Fig. 5, the vulnerability 
of the two cell lines to H2O2 was also cell-dependent. For PA-TU-8988T cells, when the H2O2 concentration was 
larger than 36.3 μM, H2O2-DMEM has significantly higher toxicity to cancer cells than H2O2-PBS. On the con-
trary, when the H2O2 concentration was larger than 72.6 μM, H2O2-PBS there was significantly more toxicity to 
for U87MG cells than H2O2-DMEM. Such cell-dependent difference is well consistent with the trends obtained 
from experiments based on PSS (Fig. 3), which again confirms that H2O2 is the main anti-cancer species in PSS 
compared with NO2−.
Figure 3. The different toxicities of PSM/PSB on cancer cells. (a) PA-TU-8988T cells. (b) U87MG cells. (c) Pre-
treating PA-TU-8988T cells with NAC. (d) Pre-treating U87MG cells. As we illustrated in Methods, PSB was 
just used to culture cells for 3 hr before using new DMEM to replace it. Results are presented as the mean ± s.d. 
of two independently repeated experiments performed in sextuplicate. Student’s t-test was performed and the 
significance is indicated as ***p < 0.005, **p < 0.01, and *p < 0.05.
www.nature.com/scientificreports/
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The rise of intracellular ROS is regarded as a key cellular response to the CAP treatment5, 58. The disturbed redox 
balance31, 54, serious DNA damage13, 59, 60, as well as mitochondria damage15, 48, 61 may be all caused by the rise of 
intracellular ROS. H2DCFDA is a common intracellular ROS probe used in plasma medicine13, 17, 48, 51, 52, 56. In this 
study, we also used H2DCFDA as the probe. Following the protocols provided by the manufacturer, the intracellu-
lar ROS measurement needs a high cell confluence (25 × 104 cells/mL). Because the cellular response to the CAP 
treatment is highly confluence-dependent21, 24, such high confluence needs a very high reactive species concen-
tration to generate an observable cellular response. Thus, 10 min-equivalent (367.5 μM) and 20 min-equivalent 
(735 μM) H2O2-rich DMEM/PBS were used to simulate the response of cancer cells to the PSS with a similar 
H2O2 concentration. For PA-TU-8988T cells, H2O2-DMEM caused a stronger intracellular ROS rise than that 
seen in H2O2-PBS (Fig. 6a). For U87MG cells, H2O2-PBS caused a stronger intracellular ROS rise than that seen 
in H2O2-DMEM (Fig. 6b). The trends observed in the rise of intracellular ROS explain the trends observed in the 
anti-cancer capacity of PSS (Figs 3a and b). The noticeable rise of intracellular ROS in the PSM-treated cancer 
Figure 4. The toxicity of NO2− on cancer cells. (a) PA-TU-8988T cells. (b) U87MG cells. Results are presented 
as the mean ± s.d. of three independently repeated experiments performed in sextuplicate.
Figure 5. The toxicity of the H2O2-DMEM and the H2O2-PBS on cancer cells. (a) PA-TU-8988T cells. (b) 
U87MG cells. As we illustrated in Methods, H2O2-PBS was just used to culture cells for 3 hr before using new 
DMEM to replace it. 36.8 μM of H2O2-PBS/DMEM is the equivalent solution of 1 min of CAP-stimulated PBS/
DMEM. Results are presented as the mean ± s.d. of three independently repeated experiments performed in 
sextuplicate.
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cells rather than in the PSB-treated cancer cells has also been observed recently30. Based on all above results, it is 
reasonable to conclude that the different toxicities of PSS on different cancer cell lines is at least partially due to 
the different rise of intracellular ROS in different cancer cells exposed to the reactive species particularly H2O2 
in PSS. An optimized strategy for using PSM and PSB in cancer treatment should therefore be cell-dependent.
In fact, DMEM a solution with abundant nutrient and PBS a solution with few nutrients should be regarded 
as the extreme cases in biologically adaptable solutions. We further identified a general trend for other biological 
adaptable solutions through investigating the dilution effect of PBS in DMEM on the anti-cancer effect of PSS. 
Following the protocols in Methods, a series of diluted DMEM solutions were made by increasing the volume 
fraction of PBS in DMEM from 0% (v/v) to be 90% (v/v). The volume fraction is also named as the dilution 
fraction or the dilutability in this study. The dilution effect on the killing effect of PSM over MDA-MB-231 cells, 
PA-TU-8988T cells, as well as U87MG cells were studied. Despite the dilution on DMEM did not change the 
H2O2 concentration in PSS (Fig. 7a), the dilution effect showed a remarkable impact on the anti-cancer capacity 
of PSS. For MDA-MB-231 cells and PA-TU-8988T cells, the effect of cancel cell viability drastically decreased as 
the dilutability in DMEM increased when the treatment time was 1 min (Fig. 7b and c). In other words, the dilu-
tion in DMEM protected these cell lines from the attack of reactive species. When the treatment time increases 
to 2 min, a noticeable increased anti-cancer effect is obtained in all experiments with different dilution levels. The 
trend that the CAP-stimulated highly diluted DMEM is more resistant to the effect of reactive species still exists 
(Fig. 7b and c). These results indicate that the dilution effect may change the threshold of cancer cells to the effect 
of the CAP-originated species, rather than a difference in the actual CAP-originated species generated (Fig. 7a). 
For U87MG cells, the dilution effect exerts a similar but a weaker dilution effect even up to a CAP treatment 
time of 3 min (Fig. 7d). Such a difference may be due to the much stronger resistance seen in U87MG cells to the 
CAP treatment compared with PA-TU-8988T cells and MDA-MB-231 cells21, 24. However, when the dilutability 
increases from 80% to 90%, the killing effect of PPS on U87MG cells is decreased. In short, the dilution effect as a 
new factor can drastically regulate the anti-cancer capacity of PSS.
Discussion
The anti-cancer capacity of PSS mainly PSM has been demonstrated over the past 5 years. From these studies, the 
reactive species H2O2, NO2−, as well as NO3− have been regarded as the main factors affecting the death of cancer 
cells18, 20–22, 24, 26, 27, 34, 37. On the contrary, the biologically adaptable buffered solution such DMEM and PBS have 
just been regarded as a carrier for the dissolved CAP-originated reactive species16–28, 34–37. Such understanding 
can satisfactorily explain the common observation that PSM, the most commonly investigated PSS, is an effective 
anti-cancer tools on several cell lines in vitro. This explanation conflicts with the observation that directly using 
PSB to affect cells will just generate a much weaker and perhaps a negligible killing effect compared with using 
PSM30, 43.
In this study, through a comprehensive investigation on the anti-cancer effect of PSM and PSB on pancreatic 
adenocarcinoma cells and glioblastoma cells, and the rise of intracellular ROS in these cells upon the treatment 
of PSM and a PSB, we can give a comprehensive explanation to previous conflicting observations. First, the con-
centration of the main toxic reactive species H2O2 in PSM and PSB is the same (Fig. 6a). Second, both PSM and 
PSB are toxic to cancer cells as long as the CAP treatment time is adequately long, such as 4–5 min revealed in 
this study (Fig. 3a and b). Particularly for the experiment using H2O2-DMEM or H2O2-PBS, their strong toxicities 
on pancreatic adenocarcinoma cells and glioblastoma cells clearly demonstrate the reactive species such as H2O2 
can kill cancer cells culture in DMEM or PBS (Fig. 5a and b). Thus, the earliest observation that the mammalian 
cells immersed in PBS did not experience DNA damage upon the CAP treatment may be partially due to a rela-
tively weak CAP treatment dose43. Based on this study, it is reasonable to speculate that serious DNA damage and 
apoptosis in cancer cells will also occur as long as the CAP treatment is adequately long even if just PSB has been 
used to affect cancer cells.
More importantly, the anti-cancer effect of PSM/PSB is cell-dependent (Fig. 3a and b). Specifically, PSM 
is much more toxic than PSB on PA-TU-8988T cells. On the contrary, PSB is much more toxic than PSM on 
U87MG cells. And, this trend will not be changed if these cells are just treated by H2O2-DMEM and H2O2-PBS 
(Fig. 5a and b). Thus, such specific cellular response of cancer cells to PSM or PSB is at least partially determined 
Figure 6. The different intracellular ROS changes due to the H2O2 treatment. (a) PA-TU-8988T cells. (b) 
U87MG cells. Results are presented as the mean ± s.d. of two independently repeated experiments in triplicate. 
Student’s t-test was performed and the significance is indicated as ***p < 0.005, **p < 0.01, and *p < 0.05.
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by the specific cellular response of cancer cells in H2O2-containing environment. In addition, we identified that 
the rise of intracellular ROS upon the treatment of H2O2-DMEM and H2O2-PBS is also cell-dependent (Fig. 6a 
and b). Thus, the stronger rise of intracellular ROS in one cancer cell line than another cell line is also determined 
by the specific response of cancer cells to reactive species such as H2O2 in a specific extracellular environment 
such as DMEM or PBS. Based on our findings, it is reasonable to speculate that the previous conflicting obser-
vations about the stronger anti-cancer effect of PSM compared with PSB may just reflect one component of the 
whole picture revealed in this study.
Understanding the different intracellular ROS levels in pancreatic adenocarcinoma cells and glioblastoma 
cells affected by PSM and PSB may be the key to explain the distinct responses of cancer cells to PSM and PSB. 
We propose that different cellular responses in the nutrient-rich and the nutrient-starved environment may cause 
cancer cells to show different responses to the extracellular reactive species such as H2O2 (Fig. 8). When cells are 
cultured in a nutrient-rich environment such as in DMEM, most reactive species such as H2O2 may diffusion into 
the cytosol of cancer cells. The damage on the cellular membrane may be a minor factor to cause the cell death. 
Recently, we have demonstrated that the diffusion process is controlled by aquaporins; an important membrane 
channel for H2O262. Knocking out one specific aquaporin, AQP8, significantly weakens the anti-cancer capacity of 
PSM on U87MG cells62. When cells are in PBS, the nutrient starvation may force cancer cells to enter an unusual 
state. For PA-TU-8988T cells, the nutrient starvation may inhibit the transmembrane diffusion of reactive spe-
cies and inhibit the rise of intracellular ROS via an unknown mechanism. As a result, the damage on the cellular 
membrane may be stronger than that occurs in a nutrient-rich environment such as in DMEM. For U87MG cells, 
the nutrient starvation may enhance the transmembrane diffusion of reactive species and the rise of intracellu-
lar ROS also via an unknown mechanism. And, based on this model, it is possible to explain the observation in 
Fig. 3c and d that pre-treating cells with NAC can just counterpart the killing effect of PSB on U87MG cells rather 
than on PA-TU-8988T cells. Pre-treating cancer cells with NAC can just scavenge the intracellular ROS, rather 
than the extracellular ROS. In addition, the rise of intracellular ROS may also be due to other intracellular mech-
anisms, such as the generation of mitochondrial ROS in the early programmed cell death63. Further research on 
this mechanism governing the cell-dependent rise of ROS and other cellular damages such as membrane damage 
due to PSS is needed.
Figure 7. The dilution in medium by PBS significantly weakens the anti-cancer capacity of PSS in some cancer 
cell lines. (a) The concentration of H2O2 in the PSM with different dilutabilities. (b) Breast adenocarcinoma 
cell line (MDA-MB-231). (c) Pancreas adenocarcinoma cell line (PA-TU-8988T). (d) Glioblastoma cell 
line (U87MG). 0% of dilutability and 90% of dilutability represents a mixed DMEM composed of 0% (v/v) 
PBS + 100% (v/v) DMEM and a mixed DMEM composed of 90% (v/v) PBS + 10% (v/v) DMEM, respectively. 
Result in (a) presented as the mean ± s.d. of three independently repeated experiments performed in triplicate. 
Results in (b,c and d) presented as the mean ± s.d. of three independently repeated experiments performed in 
sextuplicate.
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In our previous studies, several important factors which will affect the anti-cancer capacity of PSM have been 
proposed21. These factors include the contact area between CAP and the solution, the volume of the solution, as 
well as the distance between the CAP source and the solution21. A reasonable controlling these factors will obtain 
a stronger PSM without increasing the treatment time and dose. This study demonstrates a novel important fac-
tor, the dilutability of PSS. For some cell lines such as PA-TU-8988T and MDA-MB-231, the decrease of the nutri-
ent components in DMEM will significantly weaken the anti-cancer capacity of PSM. For U87MG cells, a much 
weaker but similar trend has also observed as long as the dilution fraction is not too large; i.e. 90%. The impact of 
the dilution effect may be partially due to that fact that the cancer cells’ response to PSS is specifically determined 
by both the type of cancer cell and the components of solutions used to make PSS. In short, the biologically adapt-
able solutions such as PBS, DMEM, as well as the diluted DMEM are not just the carriers for the CAP-originated 
reactive species but also actively affect the killing process of PSS on cancer cells.
Conclusions
In summary, the anti-cancer capacity of the cold plasma-stimulated solutions is both cell-dependent and 
dilutability-dependent. Pancreatic cancer cells and glioblastoma cells are highly vulnerable to the cold 
plasma-stimulated DMEM and the cold plasma-stimulated PBS, respectively. Such cell-dependent response may 
be due to the differential rise of intracellular reactive oxygen species of cancer cells in the specific H2O2-containing 
environment. However, the cold plasma-stimulated solutions alone can be a strong anti-cancer tool as long as the 
CAP treatment is of adequate duration long. Moreover, the dilutability of the solution is a very important factor 
affecting the anti-cancer capacity of the cold plasma-stimulated solution. For pancreatic cancer cells and breast 
cancer cells, the dilution on medium will significantly weaken the toxicity of the cold plasma-stimulated medium 
over these cells. For glioblastoma cells, the dilution will not noticeably affect the anti-cancer capacity of the cold 
plasma-stimulated medium.
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